Prof. Christian Holz is an Associate Professor at the Department of Computer Science and Deputy Head of the Institute of Intelligent Interactive Systems at ETH Zürich. His work focuses on advancing human-computer interaction through innovations in wearable technologies, mixed reality systems, and sensor-driven applications. Key research areas include motion capture, physiological signal processing, and adaptive user interfaces. Holz leads the SIPLab (siplab.ethz.ch), producing influential work at the intersection of computer science and biomedical engineering. His research explores cutting-edge topics such as egocentric vision systems, wearable health monitoring devices, and VR/AR applications. Recent studies investigate cybersickness detection via EEG, heart rate estimation from eye-tracking cameras, and scalable motion capture using inertial/UWB sensors. Holz's work emphasizes practical applications in healthcare, education, and human-centered computing. Publications reflect a strong focus on interdisciplinary solutions, combining machine learning with sensor data analysis. Notable contributions include the EgoSim multi-view simulator, WildPPG biomedical dataset, and MiBOT cardiovascular modulation device. His research bridges theoretical advancements with real-world usability in domains like emergency response training, chronic disease monitoring, and immersive education.
Bobak Mortazavi is an Associate Professor in the Department of Computer Science & Engineering at Texas A&M University. His research focuses on medical analytics, machine learning, wearable sensors, and cyber-physical systems. He leads interdisciplinary projects in healthcare technology, including AI-driven diagnostics and predictive modeling for cardiovascular diseases. He has received notable awards such as the Best Demonstration Award at IEEE EMBS 2012 and the Best Paper Award at the Fourth International Conference on Data Analytics 2015. His work bridges machine learning with clinical applications, emphasizing practical solutions for healthcare challenges. Recent research includes developing AI tools for aortic stenosis detection, electrolyte estimation via ECG, and real-time patient monitoring systems. He collaborates with industry and academic partners to advance telemedicine and wearable health technologies. Key contributions include the SMART-LV project for smartphone-based cardiac diagnostics and the ArterialNet framework for blood pressure reconstruction using wearable sensors. His work is published in top journals like IEEE Journal of Biomedical and Health Informatics and Elsevier's Pervasive and Mobile Computing.
Raul Vicente Zafra is a Professor of Data Science at the University of Tartu, Faculty of Science and Technology, Institute of Computer Science, where he has been working since 2013. His research spans computational neuroscience, artificial intelligence, and data science, with a particular focus on bridging biological and artificial models of intelligence. Education: PhD in Physics (2001-2006), University of the Balearic Islands BSc in Physics (1997-2001) Professor Zafra's research interests center on computational neuroscience and artificial intelligence, with specific expertise in brain-computer interfaces, reinforcement learning, neural modeling, and explainable AI. His work bridges the gap between biological and artificial intelligence systems, exploring how neural principles can inform machine learning algorithms and vice versa. He has made significant contributions to understanding neural coherence, time interval learning in neural systems, and the application of information theory to brain-computer interfaces. His research often involves interdisciplinary collaboration between computer science, neuroscience, and medicine. Analysis of Zafra's recent publications reveals a strong focus on the intersection of artificial intelligence and neuroscience. His work spans explainable AI methods, brain-computer interfaces, reinforcement learning models that mimic cognitive processes, and neurophysiological studies of brain activity. A notable trend is his exploration of how biological principles of neural computation can inform and improve artificial intelligence systems, particularly in areas like time-based learning, consciousness modeling, and neural coherence. Scientific Awards: 2012: Attendee at the 62nd Lindau Nobel Laureate Meeting 2007: Quantum Electronics and Optics Division Prize of the European Physical Society for the best PhD Thesis in Applied Optics in Europe 2006: PhD Extraordinary Award of the Physics Department of the University of the Balearic Islands 2001: Physics Degree Extraordinary Award (First Class Honors, best GPA) 1997: Bronze Medal in the "8th Spanish Physics Olympiad" Professor Zafra has been principal investigator on numerous significant research projects including the Estonian Centre of Excellence in Artificial Intelligence, Cardiovascular Stress Impacts On Neuronal Function, and Bridging biological and artificial models of vision. His grant portfolio demonstrates strong funding support from the Estonian Research Council, European Commission, and other major funding bodies. He has supervised multiple PhD students and mentored early-career researchers in computational neuroscience and AI. His laboratory work focuses on developing computational models of neural systems and applying these insights to artificial intelligence. Current research directions include explainable AI methods, brain-computer interfaces, modeling of consciousness and cognitive processes, and the application of AI to healthcare challenges.
Artur W. Dubrawski is an Alumni Research Professor of Computer Science and Director of the Auton Lab at Carnegie Mellon University's School of Computer Science. He leads interdisciplinary research on Artificial Intelligence, Machine Learning, and Robotics with real-world applications in healthcare, nuclear safety, food safety, and counter-human trafficking. His work focuses on bridging gaps between data-driven AI and empirical sciences through probabilistic modeling, predictive analytics, and time-series intelligence. Lab: Auton Lab (founded 1993) Collaborations: Allegheny County Health Department, USDA, CDC, U.S. Army Research Impact: AI for wastewater-based COVID-19 forecasting, radiological inspection systems, and hospital infection detection His students and affiliates include current PhD candidates Angela Chen, Emma Erickson, Cecilia Morales, Willa Potosnak and past researchers like Benedikt Boecking (co-inventor of Interactive Weak Supervision). The lab has spun off startups like Marinus Analytics (IBM XPrize finalists) and developed open-source tools like auton-survival for survival analysis. Key Grants: $10.5M U.S. Army contract for AI-driven predictive maintenance research.
Ji Zhu is the Susan A. Murphy Collegiate Professor of Statistics at the University of Michigan, Department of Statistics. He holds affiliations with the Michigan Institute for Data Science (MIDAS) and the Michigan Integrated Center for Health Analytics and Medical Prediction (MiCHAMP). His research focuses on statistical machine learning, network analysis, and health science applications. Education: B.Sc. in Physics (Peking University, 1996), M.Sc. and Ph.D. in Statistics (Stanford University, 2000 and 2003). Notable awards include the NSF CAREER Award (2008), Fellowships from the ASA (2013) and IMS (2015), and recognition as a Web of Science Highly Cited Researcher (2014–2020). Research interests span statistical methodologies for networks, survival analysis, and high-dimensional data. He co-authored influential papers on community detection, network cross-validation, and latent space models. Current editorial roles include Editor-in-Chief of the Annals of Applied Statistics and Action Editor for the Journal of Machine Learning Research. Advising: Supervised over 50 students and postdocs, many now in academia and industry. Notable former advisees include Tianxi Li (University of Minnesota), Yuan Zhang (Ohio State University), and Weijing Tang (Carnegie Mellon University). Labs/Teams: Active in interdisciplinary projects at MIDAS and MiCHAMP, focusing on healthcare analytics and predictive modeling for diseases like hepatitis and cardiovascular outcomes.
Dr. Samira Lakhal-Littleton is an Associate Professor of Cell Physiology and MRC Senior Non-Clinical Research Fellow at the University of Oxford, affiliated with the Department of Physiology, Anatomy and Genetics and Brasenose College. Her research focuses on iron homeostasis, systems biology, and oxygen sensing mechanisms in cardiovascular and systemic physiology. Education: BSc in Human Genetics (University College London), DPhil in Molecular Medicine (University of Oxford) Her work bridges cell physiology and translational medicine, with key discoveries on hypoxia-inducible factors (HIFs), iron regulatory genes TMPRSS6 and GDF15 , and the role of hepcidin in altitude adaptation and chronic diseases. She utilizes tissue-specific animal models to study iron regulation in heart, kidney, placenta, and vasculature. Recent publications highlight her contributions to understanding: FLASH radiotherapy effects linked to iron-dependent lipid peroxidation Clinical implications of myocardial iron dynamics in heart failure Hepcidin's role in vascular protection and placental iron transfer Biomarker development for predictive iron deficiency diagnostics Scientific Leadership: British Heart Foundation Intermediate Fellowship (2012) MRC Senior Fellowship (2020) BioIron Society Board Member (2019) She collaborates with clinical teams on translational projects and serves as a Tutorial Fellow in Medicine at Brasenose College, mentoring students in physiological sciences.
Prof. Dr. Dennis Säring is a faculty member at the University of Applied Sciences Wedel , specifically affiliated with the School of Engineering. His academic and research activities focus on Deep Learning , Medical Image Analysis , and applications of Artificial Intelligence in healthcare and biomedical imaging. He has led seminars on Deep Learning topics and supervised student projects in Autonomous Driving at Audi's AADC 2018 competition. Research Highlights : Cardiovascular imaging, forensic age estimation via MRI, neural network-based bone segmentation, and cerebrovascular aneurysm analysis. Technical Expertise : Cardiac MRI, 3D/4D image processing, parametric mapping, and spatiotemporal data fusion. His recent publications (2018-2023) emphasize 3D MR segmentation for age assessment, CMR strain analysis in athletes, and T1/T2 mapping for myocarditis. Key collaborations include institutions like the University Medical Center Hamburg-Eppendorf and Wedler Hochschulbund, with funding for autonomous vehicle research. While no explicit scientific awards are listed, his work spans clinical cardiology, forensic radiology, and AI-driven medical diagnostics.
Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.
Michael Yeager, PhD, serves as an Associate Clinical Professor in the School of Medicine at the University of Colorado Denver, focusing on cardiopulmonary pathophysiology with emphasis on pulmonary hypertension and heart failure mechanisms. He completed his PhD at the University of Colorado Health Sciences Center in 2002, establishing foundational expertise in vascular biology. His research program investigates immunological and molecular drivers of pulmonary vascular disease, particularly the roles of autoantibodies, fibrocytes, and inflammatory cascades in disease progression. Analysis of his 14 publications (2012-2015) reveals consistent exploration of biomarker discovery, vascular remodeling, and immune dysregulation across pediatric and adult pulmonary hypertension. Key methodological approaches include proteomics, animal modeling, and molecular interrogation of cellular stress responses, with significant translational implications for personalized therapeutic strategies. Professional recognitions include: Outstanding Faculty award from Tau Beta Pi (2019) Chancellor's Teaching Recognition Award from the University of Colorado (2016) Dr. Yeager maintains active clinical research collaborations at Children's Hospital Colorado while mentoring within the medical school curriculum. His work bridges basic science discovery with clinical application through ongoing investigations into endothelial dysfunction and inflammatory mediators. Affiliated with the Department of Medicine, he contributes to pulmonary vascular research initiatives and participates in professional societies including the American Thoracic Society, American Heart Association, and T21 Research Society.
James Briscoe is a Senior Group Leader at The Francis Crick Institute in London, where he leads a research group focused on developmental biology and morphogen signaling. He previously held positions at the Medical Research Council's National Institute for Medical Research, which later became part of the Francis Crick Institute. Education: BSc in Microbiology and Virology from the University of Warwick, UK PhD from Imperial Cancer Research Fund/King's College London Postdoctoral training at Columbia University with Thomas Jessell Dr. Briscoe's research focuses on the molecular and cellular mechanisms of graded signaling by morphogens and the role of transcriptional networks in cell fate specification. His laboratory employs a range of experimental and computational techniques using model systems including mouse and chick embryos and embryonic stem cells. His work has significant implications for understanding developmental processes and their relationship to disease. His recent publications demonstrate a continued focus on morphogen gradients, neural tube development, and computational approaches to understanding cell fate decisions. His research increasingly integrates single-cell technologies and computational modeling to unravel the complexities of developmental patterning. Scientific Awards and Honors: EMBO Young Investigator (2001) EMBO Gold Medal (2008) Elected to EMBO (2009) Fellow of the Academy of Medical Sciences (2019) Fellow of the Royal Society (2019) As Editor-in-Chief of the journal Development since 2018, Dr. Briscoe plays a significant role in shaping the field of developmental biology. His leadership extends to mentoring researchers and contributing to scientific policy discussions, as evidenced by his recent publication 'Science under siege: protecting scientific progress in turbulent times.' Dr. Briscoe's laboratory at the Crick Institute is well-equipped with access to advanced facilities including light microscopy, flow cytometry, genomics, and computational resources, enabling a multidisciplinary approach to developmental biology questions.
Karin Allor Pfeiffer is a Professor in the Department of Kinesiology at Michigan State University (MSU) and Director of the Institute for the Study of Youth Sports. She holds additional membership in the Center for Physical Activity and Health. With a Ph.D. from MSU, her research focuses on physical activity measurement methodologies and population health interventions, particularly among children and adolescents. Her work addresses obesity prevention, environmental design impacts on activity levels, and sociocultural factors influencing youth sport participation. Education: Ph.D. in Kinesiology from Michigan State University Her research interests emphasize: - Quantitative methods for physical activity assessment - Schoolyard redesign strategies and their health impacts - Cardiometabolic risk factors in pediatric populations - Longitudinal tracking of physical fitness and health outcomes Recent work explores accelerometer fragmentation metrics, GPS-linked activity tracking, and disparities in sedentary behavior across demographic groups. She has pioneered interdisciplinary approaches integrating spatial analysis, wearable technology, and policy evaluation. Key contributions include developing the Observational System for Recording Physical Activity in Children and advancing consensus methods for accelerometer data interpretation. Her studies frequently highlight socioeconomic and environmental determinants of health behaviors. Dr. Pfeiffer collaborates with public health agencies and urban planners to translate research into actionable policies. Her lab focuses on scalable interventions for underserved communities, leveraging community-engaged methods to address greenspace accessibility and safety concerns.
Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Björn Pasternak is a Research Professor leading the Pharmacoepidemiology group at the Department of Medicine, Solna, Karolinska Institutet. His team specializes in large-scale registry studies focused on adverse drug effects, with research programs in pediatric pharmacoepidemiology, safety of diabetes medications, and rapid assessment of drug safety concerns. The group leverages high-quality epidemiological methods to inform evidence-based clinical decisions. Pasternak's research interests span pharmacoepidemiology, drug safety, diabetes outcomes, cardiovascular risk, and perinatal health. His work utilizes nationwide registries to evaluate real-world drug effects, socioeconomic disparities in treatment, and long-term outcomes of chronic therapies. Key focuses include GLP-1 receptor agonists, SGLT2 inhibitors, antibiotic use in pregnancy, and opioid safety. Recent publications demonstrate strong emphasis on Scandinavian cohort studies of diabetes medications (GLP-1 agonists, SGLT2 inhibitors) and their associations with thyroid cancer, liver events, intestinal obstruction, and cardiovascular/renal outcomes. Other trends include perinatal pharmacovigilance (antibiotics, acid-suppressive drugs) and neurodegenerative risks in athletes.
Charles E. Leonard is an Associate Professor of Epidemiology at the Perelman School of Medicine , University of Pennsylvania. He holds affiliations with multiple Penn-based institutions, including the Center for Real-World Effectiveness and Safety of Therapeutics (CREST), Institute for Translational Medicine and Therapeutics, Leonard Davis Institute, Institute on Aging, and Center of Excellence in Environmental Toxicology. Additionally, he serves as a Special Government Employee at the FDA and Honorary Lecturer at Muhimbili University of Health and Allied Sciences in Tanzania. Pharmacoepidemiology Post-market prescription drug safety Causal inference methods Real-world evidence generation Environmental health impacts on chronic disease Dr. Leonard’s research focuses on generating real-world evidence to address critical gaps in drug safety, particularly for: Population health effects of drug interactions Comparative safety of antidiabetes drugs Drug-induced sudden cardiac arrest Ambient temperature extremes and chronic disease Pharmacoepidemiology methods development His work is primarily funded by the National Institutes of Health (NIH) and has been recognized through multiple awards, including the 2024 Harold I. Feldman Distinguished Scholar Award and the 2020 Elected Fellow status at the International Society for Pharmacoepidemiology. He also contributes to curriculum development and student mentoring in Penn’s Graduate Group in Epidemiology and Biostatistics. 2024 – Harold I. Feldman Distinguished Scholar Award (Penn) 2024 – Ronald D. Mann Best Paper Award (ISPE) 2020 – Leadership Medallion (BPS) 2019 – Abraham G. Hartzema Distinguished Lecturer (University of Florida)
